Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Convergence 2020 has come and gone, but you can still access recorded sessions, which are available to attendees until 31 December 2020.
This year, our European regulatory community will converge online with a fully virtual program that will allow attendees to experience Euro Convergence live online from the safety and comfort of their homes.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 05 April 2012
A new piece of legislation released in discussion draft form by the Senate Health, Education, Labor and Pensions Committee aims to "overhaul" the US Food and Drug Administration's (FDA) Accelerated Approval pathways, reports The Hill.
Among other things, the bill would "create a new 'breakthrough' designation to provide more flexibility and certainty for developers of new medicines intended to address serious or life-threatening diseases or conditions," reports The Hill.
The draft legislation, released 4 April 2012, also includes the Advancing Breakthrough Therapies for Patients Act (ABTPA) bill released 27 March by Sens. Michael Bennet (D-CO), Richard Burr (R-NC) and Orrin Hatch (R-UT).
That legislation would "expedite FDA approval and provide more flexibility when a drug or treatment shows dramatic responses early in development, while still ensuring drug safety and efficacy," said the Senators in a statement.
The draft legislation is slated to be tacked on to the reauthorization of the Prescription Drug User Fee Act (PDUFA) legislation that must be approved before 30 September if the agency is to maintain its current level of funding.
Read more:
The Hill - Senate Health panel floats proposal for speedy FDA approval of life-saving drugs
Discussion draft: To amend the Federal Food, Drug, and Cosmetic Act with respect to certain reauthorizations
Regulatory Focus - Senators Draft Bill to Expedite Drug Approval
See all Regulatory Focus news stories about PDUFA.
Tags: Accelerated Approval Pathway, Legislation, Latest News, pharmaceutical, draft, drug, PDUFA
Regulatory Focus newsletters
All the biggest regulatory news and happenings.